GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
GSK has secured a US accelerated approval for its oral lung cancer drug neladalkib, one of two assets at the heart of its $10.6 billion purchase of oncology drugmaker Nuvalent earlier this ...
comments(0)
5-min edit window · permanent after that